Christian Hengstenberg1*, MD; Oliver Husser 2, MD, PhD
1. Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria; 2. Department of Cardiology, St.-Johannes-Hospital, Dortmund, Germany
Transcatheter aortic valve replacement (TAVR) has evolved from a last resort therapy to the standard treatment of patients with severe aortic stenosis and high risk for conventional surgery1 and has shown comparable outcomes in intermediate-risk patients2. Improvements to available transcatheter heart valves (THV), the introduction of new technologies, expansion of indication to lower-risk cohorts and increasing operator experience have resulted in a considerable decline in one-year mortality rates to below 10%3.
Despite these improvements, several issues remain to be addressed. Among these is the problem of new permanent pacemaker implantations (PPI) and new-onset conduction abnormalities (CA) after TAVI, which ...